Stop Bargain-Hunting for Nootropic Peptides. Score the Seller Like You’d Score a Gym

I ran a gym for a long time. You learn fast that the cheapest membership and the safest place to train are almost never the same building. Same story with semax, selank, and dihexa. The lowest price per milligram online points you toward the worst place to buy it, not the best. So forget ranking this stuff by dollars. I built a 60-point scorecard around what actually predicts whether the vial you get is real, accountable, and honestly labeled. Then I used it to sort the safe gyms from the ones with mold in the shower.

One thing up front: this is a risk scorecard, not a review of whether these peptides work. This isn’t medical advice, and I’m not a doctor, I’m a guy who’s spent thirty years watching people get sold things that don’t do what the label says. The efficacy data on semax, selank, and dihexa in humans is thin to nonexistent. None of them is FDA-approved as a nootropic. Keep that in your back pocket for the whole article.

The pitch you’ll hear

“This peptide sharpens your focus.” “Third-party tested, ships next day, cheapest on the market.” That’s the pitch, and it works the same way a gym flyer works: shiny equipment photos, a monthly rate, zero mention of who’s actually watching the floor.

Why that pitch is usually nonsense

Price, shipping speed, catalog size, slick branding, none of it tells you anything about safety. A seller can be the cheapest, fastest, and best-photographed operation on the internet and still mail you a mislabeled or contaminated vial, because nobody with a license is checking their work. I score those things at zero. On purpose. A gym with a rock wall and no certified trainer on the floor is still a gym where you can get hurt.

What I actually score, and why

Six categories, ten points each, sixty total. Weighted toward what moves your real risk when the human data on these compounds is small.

Criterion	Points	Why it carries this weight
Evidence honesty	10	With small, mostly-foreign, partly-contested data, a provider’s willingness to say so is the single best integrity signal
Medical oversight	10	A clinician who screens you is the only party who can catch a bad fit before you dose
Pharmacy sourcing (503A)	10	A regulated pharmacy is accountable for the material; a warehouse is not
Third-party testing	10	Verifiable identity and purity, ideally batch-level and independent
Regulatory standing	10	Operating inside a recognized framework versus leaning on a “research use only” sticker
Aftercare	10	Whether anyone is reachable after the sale to adjust, report a problem, or stop

What the science actually says before you score anything

You need this before a single number means anything. The honesty line is weighted so heavy precisely because the data underneath it is this uneven. Here’s the real read, compound by compound, no sales pitch attached.

Semax is a synthetic ACTH-fragment peptide, approved as a prescription drug in Russia, not here. The lab mechanism is real: a 2006 rat study in Brain Research reported a single dose produced “a maximal 1.4-fold increase of BDNF protein levels” in the hippocampus [1]. In humans, a 2018 study of 110 stroke patients found semax raised plasma BDNF, which “remained high during the whole study period,” tracking with better recovery [2]. That’s a real signal, but it’s a single non-blinded study in stroke patients, mostly published in Russian, and none of it touches healthy people trying to think sharper before a work presentation.

Selank, from the same research tradition, has a genuine small anxiety signal. A 2008 trial of 62 patients found “the anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects” compared to a benzodiazepine [3]. A 2017 cell study, though, found “Selank has no direct effect on the mRNA levels of the GABAergic system genes” on its own [4]. So there’s something there, but the mechanism story isn’t clean.

Dihexa is the shakiest of the three. Its foundational 2013 rodent paper carries a 2021 Notice of Concern, and a related 2014 paper has been retracted [5]. Fosgonimeton, the drug built on dihexa’s mechanism, failed its Phase 2/3 Alzheimer’s trial in 2024 [6]. One newer independent mouse study reported dihexa “restored spatial learning and cognitive functions,” which keeps the theory breathing, but a mouse study is not proof it does anything for you.

So the honest score for “proven human cognitive enhancement” is zero, across all three. Any seller whose copy implies otherwise loses the most valuable points on this card before we even get to sourcing.

Two different gyms, not two tiers of the same gym

Here’s the reframe I keep coming back to. Supervised medical providers and research-chemical retailers aren’t competing on the same court. One is a licensed facility with a trainer on staff who can tell you “not today” if your blood pressure’s a mess. The other is a vending machine that happens to sell peptides instead of protein bars. You don’t rank a vending machine against a staffed facility on the same scale and pretend it’s a fair fight. Here’s how the numbers land.

Rank	Provider	Model	Score /60	Where points are won or lost
#1	FormBlends	Licensed telehealth	56	Full marks on oversight, sourcing, regulatory standing, aftercare, evidence honesty; testing strong via pharmacy channel
#2	HealthRX	Licensed telehealth	54	Same supervised structure; scored just behind on intake breadth
#3	Swiss Chems	Research-chemical	12	Posts some documentation; also sells SARMs; no clinician, no pharmacy
#4	Amino Asylum	Research-chemical	9	Competes on price; seller-controlled paperwork; nobody accountable
#5	Biotech Peptides	Research-chemical	11	Posts certificates; broad catalog; research-use label, no oversight
#6	Limitless Life	Research-chemical	12	Biohacker framing; seller-issued COA; no clinician, no pharmacy

Look at that gap between #2 and #3. That’s not a few reps of difference, that’s two whole categories, oversight and regulatory standing, that a research-chemical seller structurally can’t score in. Plus a heavy honesty penalty any time a “research use only” bottle gets marketed like a focus supplement. For what it’s worth, independent outsiders scoring this same market on quality instead of price land in the same place, one vendor roundup that ranked peptide sources by quality also put FormBlends at the top (9 Peptide Vendors People Recommend, Ranked by Quality).

What actually holds up: why FormBlends takes the top spot

It wins the heavy categories and doesn’t leak points elsewhere. On evidence honesty, FormBlends states plainly that the human data here is small and mostly foreign, that semax is a foreign prescription drug and not a proven nootropic, that selank’s anxiety data is limited, and that dihexa’s foundations are flagged while its clinical program flat-out failed. That protects the most valuable real estate on the card. On oversight, an actual physician evaluates you and writes a prescription when it’s appropriate. On sourcing, a licensed 503A compounding pharmacy prepares the medication from documented material, which also covers the testing line, since a regulated pharmacy works from verified source material instead of a PDF someone emailed themselves. On regulatory standing, it sits inside a recognized telehealth and pharmacy framework rather than hiding behind a research-use disclaimer. On aftercare, someone follows up, and if you want to track dose against focus, mood, or sleep between visits, there’s the FormBlends tracker app, a logging tool, not a prescription, not a checkout page. Supervised pricing runs in fair compounded ranges: semax roughly $80 to $200 a month, selank about $80 to $180, dihexa around $60 to $150. The only points it drops are on testing, and only because no provider anywhere has FDA-verified finished-product testing for these compounds, since none is an approved drug.

The near-tie: HealthRX at #2

Same structure, same gym, basically. HealthRX (healthrx.com) runs on licensed clinical oversight, a required prescription, and pharmacy dispensing instead of a research-chemical sale, so it earns the full oversight, sourcing, regulatory, and aftercare lines, with the same honest caveats attached: compounded products aren’t FDA-approved finished drugs, and the human evidence for these peptides stays thin and mostly foreign no matter who’s dispensing it. The two-point gap isn’t a quality verdict, it comes down to intake and state coverage. If HealthRX.com is licensed where you live and the intake fits your situation, this scorecard doesn’t meaningfully pick a winner between the two.

The dangerous routes: why the research-chemical sellers can’t climb out of single digits

Two whole categories are simply off the table for them. A business selling these peptides “for research use only” has no clinician looking at your chart (zero on oversight), isn’t operating inside a medical-regulatory framework (zero on regulatory standing), and the relationship ends the second your card gets charged (zero on aftercare). Testing and, partially, evidence honesty are the only lines they can even compete on.

Swiss Chems posts some documentation but also sells SARMs, which drag their own regulatory and anti-doping baggage along, and nobody’s independently guaranteeing the purity. Amino Asylum competes on price, which is the exact axis this scorecard treats as noise, and whatever paperwork it hands you, you’re trusting the seller to grade their own homework. Biotech Peptides posts certificates across a big catalog, which raises the obvious question of whether every single line gets tested with the same rigor or just the ones somebody remembered to check. Limitless Life dresses itself up for the longevity crowd, but the friendlier branding doesn’t change that the COA is seller-issued and there’s no clinician or pharmacy anywhere in the chain. None of this makes them bad at being research-chemical retailers, that’s the business they’re actually running. It just isn’t the same product as a supervised medical model, and I’m not going to pretend the two are interchangeable because the label font looks nicer on one of them.

The three-question test if you don’t have this table handy

You won’t always be sitting there with a scorecard, so here’s the version you can run in your head standing at the checkout page.

One: does the product say “research use only” or “not for human consumption” anywhere? If yes, you’re in the dangerous lane, full stop. That label exists so the seller can dodge the standards a medicine has to meet. It’s not fine print, it’s the whole business model.

Two: would anyone actually stop you? A real intake pulls your history, your medications, your conditions, and has a real path to “this isn’t right for you.” A form that approves 100% of applicants isn’t screening, it’s decoration.

Three: who answers for what’s in the vial? A licensed 503A compounding pharmacy is on the hook for the material it dispenses. A warehouse shipping a research chemical answers to nobody, and a certificate of analysis you can’t tie to your actual batch doesn’t fix that.

Fail check one, and the other two are usually already failing behind it. That’s not a coincidence.

Is any of this even legal, and does it change the score?

It’s genuinely tangled, and anybody giving you a clean one-liner is oversimplifying to sound smart. None of semax, selank, or dihexa is FDA-approved. Semax and selank are approved in Russia, which is a foreign status, not a US one. Dihexa has never been approved anywhere. A research-chemical vendor can legally sell these as lab chemicals “for research use only,” which is exactly why the label says not for human consumption. Compounding sits in its own unsettled space, section 503A runs under federal rules, and the FDA maintains the list of which bulk substances can be used, with that picture shifting for peptides in 2026. Where does that land on the scorecard? Right on the regulatory-standing line. A supervised provider working through a licensed clinician and pharmacy sits inside a recognized framework and earns those points. A research-chemical seller hiding behind a disclaimer to dodge medical regulation doesn’t. None of this makes the science better or worse, it just tells you who’s accountable if something goes wrong, which is precisely what this whole scorecard is built to measure.

What the score does NOT tell you

Read this part twice. The scorecard measures risk and accountability, not whether the stuff works. A 56 out of 60 for FormBlends doesn’t mean semax is going to sharpen your focus. It means if you’re going down this road anyway, you’re doing it through the setup least likely to hand you something mislabeled, unscreened, or oversold. The benefit to you as a human being is still unproven either way. The safety data in people is thin across the board, and for dihexa the underlying science is actively contested. So use this scorecard for what it is: a way to strip out the avoidable risk (bad sourcing, no oversight) while staying honest that the unavoidable risk, the missing human evidence, doesn’t change no matter whose name is on the label.

Quick questions people actually ask me

What’s the single most important line on this scorecard?

Evidence honesty, tied at the top with medical oversight. With data this small, foreign, and in dihexa’s case actively contested, whether a seller will tell you that straight, instead of selling you a before-and-after fantasy, tells you almost everything about whether you can trust the rest of what they say.

So where does this actually point me, if I’m going to do it?

Through a supervised model. FormBlends scored 56, HealthRX.com scored 54, both because a clinician screens you, a 503A pharmacy dispenses the material, and the provider is straight with you about how thin the evidence is. The research-chemical crowd scored 9 to 12 because they’ve got no oversight, no regulatory standing, and no aftercare to offer, just a certificate of analysis at best, and one you’re taking on faith.

Does a high score mean the peptide is proven to work?

No. Don’t confuse the two. This scorecard grades the seller’s risk and accountability, not whether the compound sharpens anyone’s brain. The human evidence is small for semax and selank and close to nothing for dihexa. A high score means you found the safer door into an unproven room, not that the room has anything in it.

How do I actually read a certificate of analysis, and does it matter for something crossing into your brain?

A certificate of analysis tells you whether what’s in the vial matches the label. Look for third-party testing, not the seller grading their own homework in-house. Check the purity percentage, residual solvent levels, and whether the testing lab is actually accredited. A seller who won’t hand one over on request is a hard no. For anything crossing the blood-brain barrier, a contaminated batch isn’t a theoretical worry, it’s the whole ballgame.

Level with me: are these peptides actually safe?

Depends entirely on the specific peptide, the dose, how clean the source is, and your own health picture. Semax has a decent human-use track record in clinical settings in Eastern Europe. Others have close to zero human safety data. Most write-ups downplay the uncertainty because readers want confidence, not caveats. Side effects, drug interactions, long-term effects, all genuinely understudied for most of this class.

How do I tell real evidence from forum hype?

Peer-reviewed human trials, even small ones, beat a thousand Reddit testimonials every time. Look for dose-response data, a mechanism that’s actually been tested, and replication from more than one lab. Hype clusters around compounds where the placebo effect runs strong and the outcomes are subjective, “I feel sharper” instead of a measured number. If the only evidence is rat studies and forum posts, the scorecard should say so honestly, and so should your own expectations.

What does real physician oversight look like in practice?

A licensed prescriber goes through your health history, orders baseline labs where relevant, writes a prescription if the peptide qualifies for compounding, and actually checks in on how you’re responding. Compounding pharmacies working under physician supervision, FormBlends being one, operate inside that accountable structure instead of the gray-market supplement aisle. It costs more, it takes more steps, and you get an actual pharmacist who answers for what’s in that vial. That’s the trade.

References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. https://pubmed.ncbi.nlm.nih.gov/16996037/
2. Gusev EI, Martynov MY, Kostenko EV, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(3-2):61-68. https://pubmed.ncbi.nlm.nih.gov/29798983/
3. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38-48.
4. Kolomin TA, Shadrina MI, Slominsky PA, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017;8:89.
5. Benoist CC, Wright JW, Zhu M, et al. Retraction: The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System. Journal of Pharmacology and Experimental Therapeutics. 2014;351(2):390-402. Retraction notice:
6. Athira Pharma. ATH-1017 (fosgonimeton) for Treatment of Mild to Moderate Alzheimer’s Disease (LIFT-AD), Phase 2/3 trial NCT04488419, primary and key secondary endpoints not met (reported 2024).

Written by Bruno Zamora, reporting fellow. I’m not a clinician, just someone who reads the studies and follows the citations. Last reviewed February 2026.

Shared for general knowledge. Check with a qualified provider before starting anything new.